1. Craddy P, Palin H-J, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5:1–41.
2. Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J. Endocrinol Metab. 2016;20:254–67.
3. Baggio LL, Drucker DJ, Andryuk PJ, Lu K, Stein P, Khatami H, et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.
4. Semaan D. In vitro anti-diabetic and anti-obesity activities of compounds from the Cuban medicinal plant, Allophylus cominia (L.) Sw. University of Strathclyde; 2014.
5. Chakrabarti R, Bhavtaran S, Narendra P, Varghese N, Vanchhawng L. Sham Shihabudeen MH, et al. Dipeptidyl Peptidase-IV Inhibitory Activity of Berberis aristata. 2011;4:158–63.